All Updates

All Updates

icon
Filter
Funding
Mainz Biomed raises USD 50 million through pre-paid advance agreement
Precision Medicine
Jun 29, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

Jun 29, 2023

Mainz Biomed raises USD 50 million through pre-paid advance agreement

Funding

  • Molecular genetics diagnostic company Mainz Biomed raised USD 50 million through a Pre-Paid Advance Agreement (PPA) with Yorkville Advisors Global. Additionally, it has entered a USD 5.5 million Promissory Note, with USD 5.0 million already funded at the time of closing. This brings the total funds raised to USD 72.5 million.

  • The funding will provide support for Mainz Biomed's commercial and product development plans, offering flexibility for strategic and opportunistic operations.

  • Mainz Biomed is a specialized company focused on early cancer detection, with a particular emphasis on colorectal cancer (CRC). Its flagship product, ColoAlert, is an at-home screening kit for CRC. The company follows a unique business model by partnering with third-party laboratories for test kit processing. In addition to commercializing ColoAlert, Mainz Biomed is actively conducting clinical studies for a CRC screening test. Furthermore, it has an early-stage product pipeline that includes a screening test specifically designed for pancreatic cancer.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.